Compare · PXMD vs TLRY
PXMD vs TLRY
Side-by-side comparison of PaxMedica Inc. (PXMD) and Tilray Brands Inc. (TLRY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PXMD and TLRY operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- TLRY carries a market cap of $2.44B.
- Over the past year, PXMD is up 0.0% and TLRY is up 41.0% - TLRY leads by 41.0 points.
- TLRY has hit the wire 12 times in the past 4 weeks while PXMD has been quiet.
- TLRY has more recent analyst coverage (14 ratings vs 0 for PXMD).
- Company
- PaxMedica Inc.
- Tilray Brands Inc.
- Price
- $0.72-3.73%
- $6.74-2.67%
- Market cap
- -
- $2.44B
- 1M return
- +0.00%
- -3.23%
- 1Y return
- +0.00%
- +40.96%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2018
- News (4w)
- 0
- 12
- Recent ratings
- 0
- 14
Tilray Brands Inc.
Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. The company offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Aphria Inc. Tilray, Inc. was incorporated in 2018 and is based in New York, New York.
Latest PXMD
- PaxMedica Inc. filed SEC Form 8-K: Leadership Update
- PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
- Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.
- SEC Form NT 10-Q filed by PaxMedica Inc.
- SEC Form EFFECT filed by PaxMedica Inc.
- SEC Form S-1 filed by PaxMedica Inc.
- SEC Form 10-Q filed by PaxMedica Inc.
- PaxMedica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
- PaxMedica Secures Immediate Exercise of Warrants
- PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
Latest TLRY
- Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
- BrewDog USA Doubles Down on Headliners and Ignites Next Wave of Innovation for Spring and Summer
- SEC Form 4 filed by Hopkinson David G.
- Tilray Brands Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B7 filed by Tilray Brands Inc.
- Tilray Brands Marks 4/20, Reaffirming Its Leadership in Cannabis and Commitment to Advancing Medical Care
- SEC Form 424B5 filed by Tilray Brands Inc.
- Tilray Brands Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership
- Tilray Brands Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities